Results 61 to 70 of about 822,308 (398)

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

Molecular Biology International, 2014
Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family having tyrosine kinase activity. Dimerization of the receptor results in the autophosphorylation of tyrosine residues within the cytoplasmic domain
N. Iqbal, N. Iqbal
semanticscholar   +1 more source

Epidermal growth factor-induced truncation of the epidermal growth factor receptor

Journal of Biological Chemistry, 1989
NIH-3T3 cells expressing the human epidermal growth factor (EGF) receptor were used in experiments to determine the fate of the EGF receptor in cells continuously exposed to EGF. EGF receptor was immunoprecipitated from cells labeled for 12 h with [35S] methionine in the absence or presence of 10 nM EGF.
openaire   +2 more sources

Optical fiber‐based in vivo quantification of growth factor receptors [PDF]

, 2012
BACKGROUND: Growth factor receptors such as epidermal growth factor receptor 1 and human epidermal growth receptor 2 (HER2) are overexpressed in certain cancer cells. Antibodies against these receptors (eg.
Allred, Alvarez, Bartlett, Baselga, Beatty, Cappuzzo, Carvalho, Cho, Dijkers, Elbauomy Elsheikh, Fiuza, Freier, Giamas, Gordon, Guo, Harris, Hede, Hicks, Hynes, Jacobs, Jones, Kong, Koutras, Lewis, Li, Maass, Mabuchi, Marty, Moasser, Nahta, Oude Munnink, Paik, Pauletti, Perez, Piccart-Gebhart, Pisano, Press, Rhodes, Roche, Roche, Roskoski, Ross, Schmitt, Schmitt, Seidman, Slamon, Tagliabue, Tedesco, Thomas, Thomas, Thomas, Turner, Wolff, Wolff, Xu, Zhang   +55 more
core   +1 more source

PICALM::MLLT10 translocated leukemia

FEBS Letters, EarlyView.
This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...
John M. Cullen, Antonia C. Nakatsugawa, Natalie Barton, Henry Haines, Gary S. Stein, Janet L. Stein, Daniel S. Wechsler, Jessica L. Heath   +7 more
wiley   +1 more source

Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor*

Journal of Biological Chemistry, 2002
The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been determined to 2.6-Å resolution, both with and without an EGFRK-specific inhibitor currently ...
J. Stamos, M. Sliwkowski, C. Eigenbrot
semanticscholar   +1 more source

Effects of growth factors and receptor blockade on gastrointestinal cancer [PDF]

, 2004
The advent of recombinant peptide technology offers the potential to use one or several peptides to treat a variety of gastrointestinal conditions. However, although cell culture and animal models have shown proof of concept, we are still at a relatively
Ghosh, S, Playford, RJ, Wassan, H
core   +2 more sources

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients

Acta Dermato-Venereologica
Skin toxicities caused by epidermal growth factor receptor tyrosine kinase inhibitors can affect patient quality of life and lead to treatment adjustments, including dose reduction or discontinuation.
Ji Su Lee, Jimin Woo, Tae Min Kim, Namkyu Kim, Bhumsuk Keam, Seong Jin Jo   +5 more
doaj   +1 more source

Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors

Tumor Biology, 2017
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are first-choice treatments for advanced non-small-cell lung cancer patients harboring EGFR mutations.
Huang-Chih Chang, Yu-Mu Chen, Chia-Cheng Tseng, Kuo-Tung Huang, Chin-Chou Wang, Yung-Che Chen, Chien-Hao Lai, Wen-Feng Fang, Hsu-Ching Kao, Meng-Chih Lin   +9 more
doaj   +1 more source

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. [PDF]

, 2016
Expression of the oncogenic transcription factor MYC is disproportionately elevated in triple-negative breast cancer (TNBC), as compared to estrogen receptor-, progesterone receptor- or human epidermal growth factor 2 receptor-positive (RP) breast cancer.
Anderton, Brittany, Balakrishnan, Sanjeev, Camarda, Roman, Eyob, Henok, Goga, Andrei, Kajimura, Shingo, Kohnz, Rebecca A, Krings, Gregor, Mahieu, Celine, Nomura, Daniel K, Tward, Aaron, Zhou, Alicia Y   +11 more
core   +1 more source